Childhood Seizure Disorder: Evaluation and Initial Treatment
For a child with newly diagnosed seizure disorder, begin with EEG confirmation of seizure activity and brain MRI to identify structural causes, then initiate treatment based on age and etiology—phenobarbital for neonates (except suspected channelopathy where sodium channel blockers are preferred), and individualized antiseizure medication selection for older children guided by seizure type and syndrome classification.
Initial Evaluation
Diagnostic Confirmation
- EEG is mandatory for accurate seizure diagnosis, as clinical observation alone is unreliable except for focal clonic and focal tonic seizures 1
- Obtain video recordings from witnesses/parents when possible to characterize semiology
- In neonates, conventional EEG or amplitude-integrated EEG (aEEG) should be used, as most neonatal seizures are subclinical (electrographic only) 2
Neuroimaging
Age-specific approach:
Neonates (0-29 days):
- MRI brain is the gold standard and should be obtained in all cases 3
- MRI identifies etiology in 39.8% of cases beyond what ultrasound shows and is highly predictive of neurological outcome 3
- Cranial ultrasound may serve as initial bedside evaluation if infant is unstable, but has low sensitivity for hypoxic-ischemic injury and small infarctions 3
- Diffusion-weighted imaging is most sensitive for hypoxic-ischemic encephalopathy (the most common cause, accounting for 46-65% of neonatal seizures) 3
Older children:
- MRI brain with and without contrast to detect structural abnormalities, malformations of cortical development, and other epileptogenic lesions
Laboratory and Genetic Testing
- In neonates, obtain comprehensive metabolic panel, glucose, calcium, magnesium, and consider genetic testing (epilepsy panel or trio whole exome sequencing) 4
- Screen for inborn errors of metabolism when indicated
- Consider pyridoxine trial in neonates with unexplained seizures not responding to second-line therapy 1
Initial Treatment
Neonatal Seizures (0-29 days)
First-line therapy:
- Phenobarbital is the first-line antiseizure medication regardless of etiology 1
- Dose: 20 mg/kg loading dose
- Phenobarbital achieves seizure cessation in 80% of neonates versus only 28% with levetiracetam 1
- Exception: If channelopathy is suspected due to positive family history (e.g., self-limited familial neonatal epilepsy), use sodium channel blocker (phenytoin or carbamazepine) as first-line 1
Second-line therapy (if seizures persist):
- Phenytoin or levetiracetam for most etiologies (HIE, stroke, hemorrhage) 1
- Alternative options: midazolam or lidocaine
- If channelopathy suspected based on clinical or EEG features: use sodium channel blocker (phenytoin or carbamazepine) 1
- If cardiac disorders present: prefer levetiracetam 1
Special considerations:
- Consider pyridoxine trial (add-on to ASM) if vitamin B6-dependent epilepsy suspected or if seizures don't respond to second-line therapy without identified etiology 1
- In neonates with hypoxic-ischemic encephalopathy, therapeutic hypothermia reduces seizure burden 1
Duration of treatment:
- Discontinue antiseizure medications before discharge home for acute provoked seizures without evidence of neonatal-onset epilepsy 1
- This applies regardless of MRI or EEG background abnormalities 1
- Early discontinuation minimizes exposure to phenobarbital, which has potential adverse neurodevelopmental effects 1
Older Children
Treatment selection depends on:
- Seizure type classification (focal vs. generalized)
- Epilepsy syndrome identification
- Underlying etiology
- Comorbid conditions
Key principle: Accurate seizure type and syndrome classification guides medication selection, as different antiseizure medications have varying efficacy for specific seizure types 2
Critical Pitfalls to Avoid
Do not treat without EEG confirmation in neonates—clinical diagnosis alone leads to treating non-seizure events and missing electrographic-only seizures 1
Do not continue phenobarbital unnecessarily in neonates with acute provoked seizures that have resolved—early discontinuation is recommended to minimize neurodevelopmental risks 1
Do not use levetiracetam as first-line in neonates unless channelopathy with cardiac involvement—phenobarbital is significantly more effective (80% vs 28% seizure cessation) 1
Do not delay sodium channel blocker if strong family history suggests channelopathy—phenobarbital may be ineffective and delay appropriate treatment 1
Recognize that treatment of all seizures (both electrographic and electroclinical) is associated with better neurodevelopmental outcomes and reduced likelihood of epilepsy later in life 1